First Targeted Therapy To Produce Remission Of Metastatic Melanoma Apr 22, 2008
The study, which shows the combination of paclitaxel and carboplatin (PC) appears. (Sep. (Science Daily)
Poniard Pharmaceuticals' Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial Apr 14, 2008
The Company also announced findings from a preclinical study demonstrating that picoplatin retains its activity in small cell lung cancer (SCLC) cell lines made resistant by treatment with cisplatin, carboplatin or oxaliplatin ... In the preclinical study presented at the AACR Annual Meeting, Poniard scientists generated resistant SCLC cell lines by repeatedly exposing the cells to cisplatin, carboplatin, oxaliplatin and picoplatin ... According to Dr. De Jager, "The data supports the possible... (PR Newswire)
High-Dose Chemo Fails Against Small Cell Lung Cancers Apr 11, 2008
The study, lead by Dr. Serge Leyvraz of the University Hospital in Lausanne, Switzerland, compared high-dose and standard-dose chemotherapy using the drug agents: ifosfamide, carboplatin and etoposide (ICE). The survival rates in the group were similar: 18 percent of the high-dose patients were alive after three years, 19 percent of standard-dose patients survived. (MEDLINEplus)
European Regulatory Agency Accepts Cell Therapeutics, Inc.'s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review Apr 2, 2008
STELLAR 3 tested carboplatin in combination with either XYOTAX or paclitaxel for the potential first-line treatment of PS2 patients with NSCLC. STELLAR 4 tested XYOTAX versus either gemcitabine or vinorelbine for the potential first-line treatment of PS2 patients with NSCLC. While the STELLAR trials missed their primary endpoint of superior overall survival, the trials showed significant reductions in most of the severe toxicities associated with standard chemotherapy agents. About Cell... (PR Newswire)
Better Regulation Of Home Genetic Tests Needed, Researchers Urge Mar 17, 2008
2, 2004) Genetic variations in an individual's ability to repair DNA damage may help predict survival in lung cancer patients treated with the common chemotherapy drugs cisplatin or carboplatin, a new. . (Science Daily)
Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM) Mar 4, 2008
STELLAR 3 tested carboplatin in combination with either XYOTAX or paclitaxel for the potential first-line treatment of PS2 patients with NSCLC. STELLAR 4 tested XYOTAX versus either gemcitabine or vinorelbine for the potential first-line treatment of PS2 patients with NSCLC. About Cell Therapeutics, Inc. Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional... (PR Newswire)
Adherex Receives Orphan Drug Designation for ADH-1 in Melanoma Feb 22, 2008
Another Phase I trial is also nearing completion at US Oncology in which systemic ADH-1 is being evaluated in combination with three different systemic chemotherapies: ADH-1 + docetaxel (Taxotere), ADH-1 + carboplatin, and ADH-1 + capecitabine (Xeloda). Subsequent Phase II and potential randomized, prospective trials of ADH-1 in combination with chemotherapy will be planned and based upon the results of the combination studies currently ongoing. (CCNMatthews Press Releases)
Onyx's Double Dose of Trouble Feb 22, 2008
No escapeWhen I saw Monday's announcement that Onyx and its partner Bayer were stopping their phase 3 clinical trial -- dubbed ESCAPE (Evaluation of Sorafenib, Carboplatin And Paclitaxel Efficacy in NSCLC) -- I figured that Nexavar had met its primary endpoint early, as it's done multiple times before ... The trial compared Nexavar to placebo with all the patients getting the standard chemotherapeutic agents carboplatin and paclitaxel, both generic versions of drugs from Bristol-Myers Squibb... (MSNBC -- Business)
UK study uncovers clue to cancer drug resistance Feb 14, 2008
Ironically, this also renders them extremely sensitive, at least initially, to cancer drugs that damage DNA, such as PARP inhibitors and carboplatin. But BRCA2 cancers can quickly become resistant to these therapies. (Cancer Research UK - News & Resources)
Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008 Feb 12, 2008
The clinical trial of XYOTAX in combination with carboplatin in women with pre-menopausal estradiol levels who have first-line non-small cell lung cancer, known as the PGT307 trial, will be limited to U.S. sites only, until either approval of the MAA or until positive results from the GOG212 trial are reported. Results of the pixantrone phase III clinical trial in aggressive, relapsed non-Hodgkin's lymphoma (NHL), known as the EXTEND or PIX301 trial, are expected in the summer of 2008. (PR Newswire)
Pre-emptive strike on cancer hope Feb 11, 2008
Drugs, such as PARP inhibitors and the platinum-based chemotherapy drug, carboplatin, have been shown to be particularly effective against BRAC2 tumours in early laboratory trials. They work by causing yet more DNA damage, tipping the cancer cells over the edge and killing them off. (BBC News -- Health)
Study reveals why certain ovarian cancers develop resistance to platinum-based chemotherapy Feb 11, 2008
SEATTLE A team of researchers led by Fred Hutchinson Cancer Research Center has identified a new mechanism that explains why some recurrent ovarian tumors become resistant to treatment with commonly used platinum-based chemotherapy drugs such as cisplatin and carboplatin ... At the same time, such mutations also make cancer cells more vulnerable to DNA-damaging agents such as cisplatin and carboplatin. (EurekAlert!)
Genes May Be Key to Lung Cancer Care Jan 18, 2008
All of the volunteers received the same "classic combination" of chemotherapy agents: carboplatin, a platinum-based drug that damages the DNA of tumor cells, and paclitaxel (sold under the name Taxol), which disrupts tumor cell division, marking them for programmed cell death. After one year, more than 50 percent of the Japanese patients were still alive, compared with only 37 percent of the Americans, who were mostly white. (Scientific American)
Ovarian cancer Dec 16, 2007
----------------- ----------------- RELATED BBC SITES. Last Updated: Friday, 30 January 2004, 11:00 GMT. (BBC News -- Health)
CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End-of-Phase II Meeting with FDA Dec 11, 2007
"We are also excited about the previously reported activity of belinostat in combination with carboplatin and paclitaxel for the treatment of recurrent ovarian cancer. We are working with our advisors to define the next steps in this indication, and look forward to presenting additional Phase II data and clinical development plans in 2008." Summary of Phase II (CLN-6) Trial Results at ASH In a poster entitled, "Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous... (PR Newswire)
Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results Nov 8, 2007
Recent Events -- Announced agreement to acquire ZEVALIN(R) (ibritumomab tiuxetan), the first FDA-approved radioimmunotherapy, from Biogen Idec; this acquisition, if completed, will return CTI to a select group of only a few biotech companies which market and sell a commercial product -- Announced a potential abbreviated registration path for pixantrone based on the Company's decision to do a full analysis of the EXTEND (PIX301) phase III clinical trial for patients with relapsed, aggressive... (PR Newswire)
New Treatment Option Studied For Bladder Cancer Nov 1, 2007
A chemotherapy regimen that includes the drug carboplatin instead of cisplatin both platinum-based compounds that also keep cancer cells from dividing is more kidney friendly but less effective than the cisplatin regimen, studies have shown. Bristol-Myers Squibb produces cisplatin and carboplatin. (Science Daily)
Promising Cancer Treatments Under Development Nov 1, 2007
Weekly treatment with a combination of paclitaxel, estramustine, and carboplatin was the most successful of the four regimens. "In our view, the results of this trial provide an objective basis for phase III evaluation of [paclitaxel, estramustine, and carboplatin] versus the current standard of single-agent docetaxel," the authors write. (Science Daily)
Three Chemo Drugs Better Than Two for Advanced Head/Neck Cancers Oct 31, 2007
People in both groups then received seven weeks of weekly chemoradiotherapy (chemotherapy and radiation combined) with carboplatin, and radiotherapy (radiation treatment) for five days a week. Those who became eligible for surgery were able to have surgery six to 12 weeks after completing chemoradiotherapy. (MEDLINEplus)
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer Oct 25, 2007
Methods We randomly assigned 501 patients (all of whom had stage III or IV disease with no distant metastases and tumors considered to be unresectable or were candidates for organ preservation) to receive either TPF or PF induction chemotherapy, followed by chemoradiotherapy with weekly carboplatin therapy and radiotherapy for 5 days per week. The primary end point was overall survival. (New England Journal of Medicine)
First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs Oct 24, 2007
SAN FRANCISCO, Oct. 24 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) announced preclinical data presented at the 19th annual AACR-NCI-EORTC Symposium show its bis-platinate drug candidates, CT-47613 and CT-47609, kill tumors refractory to currently marketed platinum agents carboplatin, cisplatin and oxaliplatin ... When tested in animal models of ovarian cancer and colon cancer, the bis-platinates were significantly more potent than the two most commonly used... (PR Newswire)
Tarceva(R) (erlotinib) Earns Approval for Lung Cancer Patients in Japan Oct 22, 2007
Results from two earlier large, randomized, placebo-controlled Phase III clinical trials in first-line advanced NSCLC patients showed no clinical benefit with concurrent administration of Tarceva with doublet platinum-based chemotherapy (carboplatin and paclitaxel or gemcitabine and cisplatin) and its use is not recommended in that setting. There have been infrequent reports of serious Interstitial Lung Disease (ILD)-like events, including fatalities, in patients receiving Tarceva for treatment... (BusinessWire)
Taxotere Gets FDA Approval For Advance Head And Neck Cancer Before ... Oct 2, 2007
Both the TPG and PF groups were given chemotherapy (carboplatin) every week combined with radiation therapy for a total of seven weeks. This was then followed by surgery for those patients identified as candidates. (Medical News Today)
Kristin Hoke: Fighting again Sep 30, 2007
Boosting her energy, she says, is the fact that her weekly chemotherapy treatments, a drug combo of carboplatin and Abraxane, seem to be hitting their mark. She says her doctors have told her the cancer, which she'll describe only as "lots of little dots," has been dramatically reduced after just a few treatments. (The Palm Beach Post)
New Chemotherapy Regimen Prolongs Survival In Difficult-to-treat Childhood Brainstem Gliomas Sep 27, 2007
Dr Mora, who is head of the department of paediatric oncology at Hospital Sant Joan de Deu, Barcelona, Spain, explained: "The main treatment for BSGs is radiotherapy. Surgery is not really an option because of the way the tumour is situated in life-threatening anatomical structures situated in the brain stem. However, for children the long-term adverse consequences of radiotherapy have meant that doctors have looked to clinical trials to see if chemotherapy could be substituted for radiotherapy.... (Science Daily)
Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer Sep 24, 2007
XYOTAX (TM) (paclitaxel poliglumex) will be studied in combination with carboplatin versus paclitaxel/carboplatin in female NSCLC patients with performance status of 0, 1, or 2. Paclitaxel in combination with carboplatin is the most commonly used treatment for the estimated 200,000 Americans who are diagnosed with lung cancer each year ... "In our STELLAR 3 trial we saw a survival benefit in the 70 percent of women who were pre-menopausal, where the XYOTAX/carboplatin combination increased the... (PR Newswire)
OUR OPINION: State board makes right call on Senate proposal Aug 25, 2007
Ixhqxlum wrote on Aug 24, 2007 4:25 PM:" School and specimen obtained in nursing carbocisteine and usually lungs. Specimen collection held on carboplatin test that carboprost addresses the cardanon adulthood. Can last often preceded capecitabine one of of fatigue capex future. Proteases of with men capla of corona capoten craving. During an with outside qualified to capreomycin episode. Recent events were accepting they suffered drinkers. What we permanent marking the source closes down... (Demopolis Times, AL)
Avastin Approved in Europe for First-line Treatment of Patients With Advanced Lung Cancer Aug 24, 2007
Patients receiving Avastin in combination with paclitaxel and carboplatin had a 25% improvement in overall survival compared to patients who received chemotherapy alone. Side effects were generally manageable. (Canada Newswire)
EGFR associated expression profiles vary with breast tumor subtype Jul 31, 2007
The basal-like tumor derived lines were also the most sensitive to carboplatin, which acted synergistically with cetuximab ... These results suggest that breast basal-like cell lines are sensitive to EGFR inhibitors and carboplatin, and this combination may also be synergistic. (BioMed Central)
Advanced Therapy Offers Cure For Relapsed Cancer Patient Jul 27, 2007
The patients received carboplatin chemotherapy at five times the dosage administered to men receiving initial therapy. A side effect of the high dosage is a reduction of blood cells so a stem cell transplant is given to replenish the body's immune system through a process similar to a blood transfusion. (Science Daily)
Salvage Therapy for Metastatic Germ-Cell Tumors Jul 26, 2007
We gave 173 patients two consecutive courses of high-dose chemotherapy consisting of 700 mg of carboplatin per square meter of body-surface area and 750 mg of etoposide per square meter, each for 3 consecutive days, and each followed by an infusion of autologous peripheral-blood hematopoietic stem cells; the other 11 patients received a single course of this treatment. In 110 patients, cytoreduction with one or two courses of vinblastine plus ifosfamide plus cisplatin preceded the high-dose... (New England Journal of Medicine)
Avastin(R) Receives Positive Opinion in Europe for First-Line Treatment of Patients With Advanced Lung Cancer Jul 20, 2007
Patients receiving Avastin at a dose of 15 mg/kg every three weeks plus paclitaxel and carboplatin had a 25% improvement in overall survival, compared to patients who received chemotherapy alone. Side effects were generally manageable. (Canada Newswire)
For Penn, the reason to hire is Cleare Jul 14, 2007
He is an inventor of Carboplatin, a cancer-treatment drug that Johnson Matthey, under his watch, licensed to Bristol-Myers Squibb Co.. Cleare thinks his experience as a researcher will help him in his No. 1 priority, getting Penn's faculty to feel comfortable working with the Center for Technology Transfer. (Philadelphia Business Journal, PA)
New 'Longboat Delivery System' Could Mean More Potent Anti-cancer Drugs Jul 6, 2007
These include analogues of the widely used and extremely potent drugs cisplatin, carboplatin, and oxaliplatin. The report is scheduled for the July 11 issue of the Journal of the American Chemical Society, a weekly publication. (Science Daily)
Cisplatin Is More Effective Than Carboplatin For Treating Nonsmall Cell Lung Cancer Jun 6, 2007
Some patients with advanced non--small-cell lung cancer (NSCLC) have slightly higher survival rates when treated with the chemotherapy drug cisplatin than another platinum-based drug, carboplatin, according to a study in the June 6 Journal of the National Cancer Institute ... Most clinicians in North America prefer carboplatin to cisplatin because it has fewer side effects and is easier to administer ... Andrea Ardizzoni, M.D., of University Hospital in Parma, Italy, and colleagues conducted a... (Science Daily)
New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel Jun 5, 2007
-- Daniel Von Hoff, M.D., Chief Scientific Officer: The Complete Phase lb Clinical Trial: A Method to Accelerate New Agent Development -- Michael Teneriello, M.D., Co-Chair, Gynecologic Cancer Research Committee, US Oncology Research: Results of a Phase II evaluation of nanoparticle albumin bound paclitaxel (nab-paclitaxel) in platinum- sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer -- Patrick Timmins, III, M.D.: Preliminary results of an open-label study to... (PR Newswire)
Poniard Pharmaceuticals Announces Results of Picoplatin Phase 2 Trial That Confirm and Extend Survival Benefit in Small Cell Lung Cancer Jun 4, 2007
The SPEAR (Study of Picoplatin Efficacy After Relapse) trial is enrolling patients who are refractory to, or who have progressed within six months of completing, treatment with first-line platinum-containing chemotherapy (cisplatin or carboplatin) ... Phase 2 Study Design and Findings The open-label, multi-center Phase 2 trial was designed to confirm the clinical activity of picoplatin as second-line therapy in patients with platinum-refractory disease or platinum-resistant or platinum-sensitive... (PR Newswire)
Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients Jun 4, 2007
The Phase 3 ESCAPE (Evaluation of sorafenib, carboplatin, and paclitaxel efficacy in NSCLC) trial recently completed enrollment of more than 900 previously untreated patients with NSCLC of all histologies. "HCC is the second tumor type in which Nexavar has demonstrated a clinical benefit. We intend to move swiftly with our partner Onyx to file these data for health authority review," said Susan Kelley, MD, Vice President, Therapeutic Area Oncology, Bayer HealthCare Pharmaceuticals. (PR Newswire)
Telik Reports Results of TELCYTA(R) Assist-3 Trial Jun 4, 2007
One hundred twenty- three women were randomized to treatment with the combination of TELCYTA and carboplatin and 124 women were randomized to treatment with pegylated liposomal doxorubicin (PLD) ... As expected with a platinum-containing regimen, there were more hematologic toxicities on the TELCYTA plus carboplatin arm as compared with the PLD arm ... Patient-reported quality of life outcomes consistently favored the TELCYTA plus carboplatin arm over the PLD arm, although the differences were... (PR Newswire)
Pfizer Inc UK Regulatory Announcement: New Data Evaluating SUTENT, CP-751,871 and Axitinib in Patients with Non-Small Cell Lung Cancer Jun 4, 2007
This study evaluated 73 patients with late-stage NSCLC. 46 percent of patients treated with CP-751,871 combined with standard care (paclitaxel and carboplatin) achieved an objective response -- meaning the tumor either partially or completely disappeared. In a subset of patients with non-adenocarcinoma (a form of NSCLC), 52 percent of those receiving the combination of CP-751,871, paclitaxel and carboplatin had objective responses ... Approximately one-third (32 percent) of patients receiving... (BusinessWire)
Adherex to Present ADH-1 and Eniluracil Data at 2007 ASCO Meeting Jun 4, 2007
Adherex is evaluating the synergy of ADH-1 in combination with chemotherapy in a Phase I trial of ADH-1 in three separate combinations: ADH-1 + docetaxel (Taxotere), ADH-1 + carboplatin, and ADH-1 + capecitabine (Xeloda). A Phase I study of ADH-1 in combination with regionally infused melphalan for the treatment of melanoma is also underway. (CCNMatthews Press Releases)
Phase II study shows combination improves survival of metastatic melanoma patients Jun 4, 2007
In this study, researchers combined two chemotherapy drugs paclitaxel (Taxol) and carboplatin with bevacizumab, a drug that prevents the formation of new blood vessels and is used to treat cancer in combination with chemotherapy drugs. The combination of paclitaxel (Taxol) and carboplatin has been beneficial in treating different cancers, such as metastatic lung cancer and ovarian cancer, Dr. Perez says ... Fifty-three patients were treated with carboplatin, weekly treatments of paclitaxel... (EurekAlert!)
Study Presented at ASCO Shows Encouraging One-Year and Overall Survival Results for Phase I/II Trial of OGX-011 in Non-Small Cell Lung Cancer Jun 3, 2007
In this single-arm, open-label study, 81 patients with Stage IIIB (18 percent) or Stage IV (82 percent) NSCLC were treated with OGX-011, 78 of whom were treated at the Phase II dose of 640 mg per week by intravenous infusion, in combination with a standard first-line NSCLC chemotherapy regimen that included gemcitabine and either cisplatin or carboplatin ... The most common grade 3 or 4 hematologic toxicities were neutropenia (47 percent in combination with cisplatin and 60 percent in... (Canada Newswire)
Erbitux prolongs survival in head/neck cancer study Jun 3, 2007
Patients received Erbitux once a week plus six cycles of the common chemotherapy drugs cisplatin or carboplatin and 5-fluorouracil every three weeks. Those in the control group received the chemotherapy without Erbitux. (Scientific American)
New Treatments for Tough Cancers Show Promise Jun 3, 2007
The U.S. Food and Drug Administration approved Avastin in October to be used in combination with chemotherapy drugs carboplatin and paclitaxel ... In a third study, adding the targeted therapy Erbitux (cetuximab) to a first-line chemotherapy that included cisplatin or carboplatin extended survival for patients with head and neck cancer that had spread to other parts of the body. (Forbes)
Gene variations point to why lung cancer drugs work better in Japanese vs. US patients Jun 3, 2007
Researchers looked at DNA from 156 patients who received the chemotherapy drugs paclitaxel and carboplatin in a SWOG clinical trial and one conducted by the Japan Multicenter Trial Organization. In the trials, half the Japanese patients survived one year, while slightly more than one-third of U.S. patients did. (EurekAlert!)
Study supports activity of GEMZAR in the treatment of early-stage breast cancer Jun 3, 2007
GEMZAR in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy ... The most severe adverse events (grades 3/4) with GEMZAR plus carboplatin for the treatment of patients with advanced ovarian cancer were neutropenia (71%), thrombocytopenia (35%), leukopenia (53%), anemia (28%), nausea (6%), vomiting (6%), and constipation (7%). (EurekAlert!)
Clinical data suggest potential versatility of ALIMTA-based regimens in lung cancer Jun 3, 2007
A prospective, randomized, multicenter Phase III study was conducted to compare ALIMTA plus carboplatin with the commonly used regimen of GEMZAR (gemcitabine HC1 for injection) plus carboplatin (ASCO Abstract # 7517 ). The study, conducted by the Norwegian Lung Cancer Group, enrolled 446 chemonave patients with either stage IIIB or IV NSCLC. The primary purpose of the study was to evaluate if the ALIMTA-carboplatin combination provided increased quality-of-life benefits while offering... (EurekAlert!)
Lilly studies try to shed light on impact of race Jun 2, 2007
One study analyzed data of chemonave African-American patients with stage IIIB/IV NSCLC treated with GEMZAR in combination with carboplatin or paclitaxel (Taxol) versus patients taking carboplatin in combination with paclitaxel ... The trial was designed to compare the efficacy of GEMZAR plus carboplatin with GEMZAR plus paclitaxel and a reference regimen of carboplatin plus paclitaxel ... GEMZAR in combination with carboplatin is indicated for the treatment of patients with ad-vanced ovarian... (EurekAlert!)
New data highlighting ABRAXANE as single agent and in combination for the treatment of breast, lung and ovarian cancers to be presented at ASCO May 30, 2007
Data from company and investigator-sponsored studies in breast, lung and ovarian cancer will be presented during the poster presentations including: BREAST CANCER ------------- Randomized study comparing nab-paclitaxel with solvent-based paclitaxel in Chinese patients (pts) with metastatic breast cancer (MBC) (Abstract 1038) Poster Presentation: Saturday, June 2, 8:00 a.m. to 12:00 p.m., Room S403 Poster Discussion: Saturday, June 2, 12 p.m. to 1 p.m., Room S406 (Vista Room) NCCTG Phase II trial... (Canada Newswire)
Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Paclitaxel and Carboplatin Trial May 29, 2007
CALGARY, May 29 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) has commenced patient enrolment in its U.K. clinical trial to evaluate the anti-tumour effects of systemic administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with advanced cancers including head and neck, melanoma, lung and ovarian ... The first is an open-label, dose-escalating, non-randomized study of REOLYSIN(R) given intravenously with paclitaxel and... (PR Newswire)
Making science personal: Lilly Oncology to unveil 76 studies at ASCO 2007 May 24, 2007
ALIMTA (pemetrexed for injection) Phase III Study of ALIMTA in First-line NSCLC Abstract # 7517: June 2, 2007; 3:00 p.m. Pemetrexed + carboplatin vs. gemcitabine + carboplatin in the treatment of stage IIIB/IV NSCLC. Large Meta-analysis of Diverse Patients with NSCLC Publication: 2007 ASCO Meeting Program Effect of race on the safety and efficacy of pemetrexed therapy in locally advanced and metastatic non-small cell lung cancer (NSCLC). (EurekAlert!)
Diabetes Drug Dramatically Boosts Power Of Platinum Chemotherapy May 9, 2007
In addition to rosizitaglone, the scientists tested pioglitazone and an experimental compound made by Glaxo Smith Kline, combining each of them with cisplatin, carboplatin and oxalyplatin -- all commonly used chemotherapy drugs that destroy cancer cells by damaging their DNA. ... Carboplatin alone reduced growth of the cancer cells by about 60 percent ... Even when applied to colon cancer cells, a type of cancer not usually treated with platinum drugs, rosiglitazone and carboplatin lowered the... (Science Daily)
Cyclophosphamide metronomic chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer Apr 16, 2007
We tried palliative chemotherapy with daily low dose oral cyclophosphamide with a patient suffering from stage IIIC ovarian cancer that responded to daily cyclophosphamide (CTX) after no response to chemotherapy with paclitaxel and carboplatin as first line and progression after second line with topotecan. The progression-free survival time on daily low dose oral cyclophosphamide treatment was 65 months without side effects. (BioMed Central)
Lilly Oncology Focused on Pharmacogenomics at AACR Annual Meeting Apr 15, 2007
The most severe adverse events (grades 3/4) with GEMZAR plus carboplatin for the treatment of patients with advanced ovarian cancer were neutropenia (71%), thrombocytopenia (35%), leukopenia (53%), anemia (28%), nausea (6%), vomiting (6%), and constipation (7%). The most common adverse events (all grades) were RBC transfusion (38%), alopecia (49%), neuropathy/sensory (29%), nausea (69%), fatigue (40%), vomiting (46%), diarrhea (25%), and constipation (42%). (Canada Newswire)
Survival Data Available From ERBITUX(R) Study in First-Line Treatment of Advanced Head and Neck Cancer Apr 4, 2007
The randomized, multi-center study, known as EXTREME, studied more than 400 patients treated with ERBITUX in combination either with cisplatin plus 5-fluorouracil (5-FU) or carboplatin plus 5-FU, compared to patients treated with cisplatin plus 5-FU or carboplatin plus 5-FU alone. "We are excited by the results of this study, as it is the first large, randomized clinical trial to examine the impact of ERBITUX treatment in combination with platinum-based chemotherapy on overall survival in... (PR Newswire)
Bevacizumab for Non–Small-Cell Lung Cancer Mar 29, 2007
14 issue)1 conclude that the addition of bevacizumab to paclitaxel and carboplatin has a significant survival benefit but is associated with an increased risk of treatment-related death. According to their results, 12 patients need to be treated to prevent one death at 1 year, at the price of an excess of one death from toxic effects for every 24 patients treated. (New England Journal of Medicine)
Analysis of International Phase III Study of Avastin(R) Plus Chemotherapy Shows Improved Progression-Free Survival in Patients With Advanced Lung Cancer Feb 22, 2007
"We will continue to analyze these data to better understand the benefit and relative safety of each arm and these findings will be presented at an upcoming medical meeting." Based on an improvement in overall survival, the U.S. Food and Drug Administration (FDA) in October 2006 granted a supplemental approval for Avastin in combination with carboplatin and paclitaxel for the first-line treatment of advanced NSCLC. The U.S. approval is based on results of the Phase III E4599 trial that studied a... (PR Newswire)
Brain Tumour Therapy Feb 4, 2007
The latter prevents the neurological complications of radiotherapy and may include Carboplatin and Vincristine. Patients with low-grade oligodendrogliomas may also be offered chemotherapy. (Suite101.com)
Medulloblastoma Feb 3, 2007
High dose chemotherapy e.g. with Carboplatin, Thiotepa and Etoposide, is being investigated. This is possible by supporting the patient with stem cell rescue, because suppression of the bone marrow will occur after therapy. (Suite101.com)
Small-Cell Lung Cancer Therapy Jan 28, 2007
Therapy involves a combination of chemotherapeutic agents, which may include Etoposide and Cisplatin or Carboplatin. Local and distant spread can lead to various symptoms. (Suite101.com)
